ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 339 filers reported holding ACCELERON PHARMA INC in Q3 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $23,176,000 | +116.8% | 134,674 | +58.1% | 0.00% | +200.0% |
| Q2 2021 | $10,690,000 | +223.3% | 85,190 | +249.2% | 0.00% | – |
| Q1 2021 | $3,307,000 | +7.3% | 24,393 | +1.2% | 0.00% | – |
| Q4 2020 | $3,083,000 | +47.3% | 24,097 | +29.5% | 0.00% | – |
| Q3 2020 | $2,093,000 | -5.6% | 18,605 | -20.1% | 0.00% | – |
| Q2 2020 | $2,218,000 | -9.0% | 23,286 | -14.2% | 0.00% | -100.0% |
| Q1 2020 | $2,438,000 | -43.6% | 27,125 | -66.7% | 0.00% | 0.0% |
| Q4 2019 | $4,320,000 | +179.4% | 81,471 | +108.2% | 0.00% | – |
| Q3 2019 | $1,546,000 | +73.7% | 39,122 | +80.4% | 0.00% | – |
| Q2 2019 | $890,000 | -39.2% | 21,684 | -31.1% | 0.00% | – |
| Q1 2019 | $1,465,000 | -58.5% | 31,452 | -61.2% | 0.00% | -100.0% |
| Q4 2018 | $3,529,000 | -45.6% | 81,021 | -28.6% | 0.00% | -50.0% |
| Q3 2018 | $6,491,000 | -52.7% | 113,402 | -59.9% | 0.00% | -50.0% |
| Q2 2018 | $13,713,000 | +186.9% | 282,610 | +131.2% | 0.00% | +300.0% |
| Q1 2018 | $4,779,000 | +5.5% | 122,224 | +14.5% | 0.00% | 0.0% |
| Q4 2017 | $4,531,000 | +55.3% | 106,770 | +36.6% | 0.00% | 0.0% |
| Q3 2017 | $2,918,000 | +46.5% | 78,176 | +19.3% | 0.00% | 0.0% |
| Q2 2017 | $1,992,000 | -44.4% | 65,527 | -51.6% | 0.00% | 0.0% |
| Q1 2017 | $3,582,000 | -51.6% | 135,324 | -53.4% | 0.00% | 0.0% |
| Q4 2016 | $7,408,000 | -74.8% | 290,306 | -64.2% | 0.00% | -90.0% |
| Q3 2016 | $29,378,000 | +1646.6% | 811,749 | +1540.3% | 0.01% | +900.0% |
| Q2 2016 | $1,682,000 | -26.0% | 49,487 | -42.5% | 0.00% | 0.0% |
| Q1 2016 | $2,273,000 | +253.0% | 86,107 | +552.7% | 0.00% | – |
| Q4 2015 | $644,000 | +61.4% | 13,192 | -17.7% | 0.00% | – |
| Q3 2015 | $399,000 | -35.7% | 16,037 | -18.3% | 0.00% | – |
| Q2 2015 | $621,000 | -18.6% | 19,620 | -2.1% | 0.00% | – |
| Q1 2015 | $763,000 | -6.8% | 20,037 | -4.7% | 0.00% | – |
| Q4 2014 | $819,000 | +28.0% | 21,025 | -0.6% | 0.00% | – |
| Q3 2014 | $640,000 | -17.4% | 21,145 | -7.4% | 0.00% | – |
| Q2 2014 | $775,000 | -2.3% | 22,823 | -0.7% | 0.00% | – |
| Q1 2014 | $793,000 | -49.5% | 22,985 | -42.0% | 0.00% | -100.0% |
| Q4 2013 | $1,570,000 | – | 39,636 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |